Cargando…

Clinical Outcomes in Non–Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling

PURPOSE: To compare clinical outcomes in a cohort of patients with advanced non–small-cell lung cancer (NSCLC) with targetable genomic alterations detected using plasma-based circulating tumor DNA (ctDNA) or tumor-based next-generation sequencing (NGS) assays treated with US Food and Drug Administra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tran, Hai T., Lam, Vincent K., Elamin, Yasir Y., Hong, Lingzhi, Colen, Rivka, Elshafeey, Nabil A., Hassan, Islam S. A., Altan, Mehmet, Blumenschein, George R., Rinsurongkawong, Waree, Rivera, Melvin J., Vasquez, Mayra E., Carter, Brett W., Byers, Lauren E., Tsao, Anne S., Gibbons, Don L., Fossella, Frank, Glisson, Bonnie S., Zhang, Jianjun, Heymach, John V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2021
Materias:	ORIGINAL REPORTS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345916/ https://www.ncbi.nlm.nih.gov/pubmed/34377884 http://dx.doi.org/10.1200/PO.20.00532

Ejemplares similares

Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC
por: Wang, Kaiwen, et al.
Publicado: (2023)

Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma
por: Hong, Lingzhi, et al.
Publicado: (2022)

Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
por: Lewis, Whitney E., et al.
Publicado: (2021)

Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non–Small-Cell Lung Cancer Reveals EGFR Mutations to Be Associated With Longer Overall Survival
por: De, Brian, et al.
Publicado: (2023)

Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non–Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab
por: Liu, Yufei, et al.
Publicado: (2022)

ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC
por: Vokes, Natalie I., et al.
Publicado: (2023)

Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer
por: Negrao, Marcelo V, et al.
Publicado: (2021)

A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
por: Gay, Carl M., et al.
Publicado: (2020)

Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer
por: Hong, Lingzhi, et al.
Publicado: (2023)

Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience
por: Altan, Mehmet, et al.
Publicado: (2023)

Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer
por: Hong, Lingzhi, et al.
Publicado: (2021)

Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations
por: Ruiz-Cordero, Roberto, et al.
Publicado: (2020)

Case Report: Immune checkpoint inhibitor–induced multiorgan vasculitis successfully treated with rituximab
por: Qureshi, Sehrish, et al.
Publicado: (2023)

Structure-based classification predicts drug response in EGFR-mutant NSCLC
por: Robichaux, Jacqulyne P., et al.
Publicado: (2021)

Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer
por: Stewart, C. Allison, et al.
Publicado: (2017)

New Actions on Actionable Mutations in Lung Cancers
por: Le, Xiuning, et al.
Publicado: (2023)

Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study
por: Saad, Maliazurina B, et al.
Publicado: (2023)

Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial
por: Cascone, Tina, et al.
Publicado: (2023)

Multicenter study demonstrates radiomic features derived from magnetic resonance perfusion images identify pseudoprogression in glioblastoma
por: Elshafeey, Nabil, et al.
Publicado: (2019)

Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers
por: Colen, Rivka R, et al.
Publicado: (2021)

Author response to Cunha et al
por: Colen, Rivka R, et al.
Publicado: (2021)

Corrigendum to “Automated Feature Extraction in Brain Tumor by Magnetic Resonance Imaging Using Gaussian Mixture Models”
por: Chaddad, Ahmad, et al.
Publicado: (2017)

Single Arm, Phase II Study of Cisplatin, Docetaxel, and Erlotinib in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas
por: William, William N., et al.
Publicado: (2018)

Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma
por: Chen, Runzhe, et al.
Publicado: (2022)

Extraskeletal Myxoid Chondrosarcoma Presenting as an Intradural Spinal Mass: Report of a Rare Clinical Presentation With an Emphasis on Differential Diagnostic Considerations
por: Rao, Priya, et al.
Publicado: (2014)

ALK: a tyrosine kinase target for cancer therapy
por: Holla, Vijaykumar R., et al.
Publicado: (2017)

Posterior leukoencephalopathy following repair of an ileocecal anastomosis breakdown: a case report and review of the literature
por: Zinn, Pascal O, et al.
Publicado: (2011)

Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer
por: Nong, Jingying, et al.
Publicado: (2018)

Author Correction: Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer
por: Nong, Jingying, et al.
Publicado: (2019)

EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
por: Le, Xiuning, et al.
Publicado: (2023)

Biomarkers/Molecular Targets, Immunotherapy, and Treatments for Non–Small Cell Lung Cancer
por: Waxman, Elizabeth S., et al.
Publicado: (2016)

Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
por: Le, Xiuning, et al.
Publicado: (2023)

2245. Primary Central Nervous System Lymphoma in Patients with HIV and Non-HIV: Should We Treat Them Differently?
por: Dandachi, Dima, et al.
Publicado: (2018)

Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies
por: Cardnell, Robert J., et al.
Publicado: (2017)

Introduction to system analysis /
por: Glisson, T. H.
Publicado: (1985)

MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers
por: Alhalabi, Omar, et al.
Publicado: (2022)

A Novel Volume-Age-KPS (VAK) Glioblastoma Classification Identifies a Prognostic Cognate microRNA-Gene Signature
por: Zinn, Pascal O., et al.
Publicado: (2012)

Diffusion-weighted MR imaging histogram analysis in HIV positive and negative patients with primary central nervous system lymphoma as a predictor of outcome and tumor proliferation
por: Khan, Bilal, et al.
Publicado: (2020)

Whole Tumor Histogram Analysis Using DW MRI in Primary Central Nervous System Lymphoma Correlates with Tumor Biomarkers and Outcome
por: Chong, Insun, et al.
Publicado: (2019)

MRI-Based Radiomics and Radiogenomics in the Management of Low-Grade Gliomas: Evaluating the Evidence for a Paradigm Shift
por: Habib, Ahmed, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_29ec29e5onk0snm4fbhc2i20u9